Literature DB >> 817927

9-10-dihydroergotamine: production of antibodies and radioimmunoassay.

J Rosenthaler, H Munzer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 817927     DOI: 10.1007/BF01937784

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


× No keyword cloud information.
  2 in total

1.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

2.  ANTIBODIES TO BRADYKININ AND ANGIOTENSIN: A USE OF CARBODIIMIDES IN IMMUNOLOGY.

Authors:  T L GOODFRIEND; L LEVINE; G D FASMAN
Journal:  Science       Date:  1964-06-12       Impact factor: 47.728

  2 in total
  14 in total

1.  Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; N T Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

2.  Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay.

Authors:  T T Kleimola
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

3.  Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine.

Authors:  V Ala-Hurula
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Highly sensitive and specific radioimmunoassays for dihydroergotoxine components in plasma.

Authors:  F Collignon; P Pradelles
Journal:  Eur J Nucl Med       Date:  1984

5.  Low bioavailability as a cause of apparent failure of dihydroergotamine in orthostatic hypotension.

Authors:  I N Olver; G L Jennings; A Bobik; M Esler
Journal:  Br Med J       Date:  1980-07-26

Review 6.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.

Authors:  H de Marées; D Welzel; A de Marées; U Klotz; K U Tiedjen; G Knaup
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Ergotamine absorption and toxicity.

Authors:  D A Orton; R J Richardson
Journal:  Postgrad Med J       Date:  1982-01       Impact factor: 2.401

10.  Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.